lower pt
monday april report neg result phase
studi oral esuberaprost combin tyvaso treprostinil studi
meet primari endpoint delay time first clinic worsen event lead
discontinu esuberaprost develop disappoint result
studi mute growth prospect tyvaso note tyvaso
growth account model remov
despit disappoint result continu see trough year
sales/earn emerg pipelin highlight opco healthcar
confer updat updat model stay bullish
silver line expect esuberaprost consid compani decis
discontinu program brief press releas anticip result
fairli cut dri warrant definit discontinu like
scientif rational behind convict level trial low
henc low posit impact tyvaso growth prospect
studi design scienc day slide intend protect/
grow tyvaso franchis explor oral inhal combin
prostacyclin approach keep plasma level prostacyclin blood
plasma high consist anticip complementari pair
success would meant higher hurdl brand gener
competit potenti gener manufactur
brand gener competit may present nuanc competit
threat tyvaso sale number inhal initi bolster
franchis dri nebul formul pipelin front expect
recent acquir ralinepag also develop inhal version garner
greater focu attent best-in-class ip receptor agonist
threat tyvaso franchis overst believ due vast
experi tyvaso among pah physician/pati commun
increas number pah patient oral prostacyclin therapi orenitram
uptravi tyvaso usag stay steady-st due increas number
patient progress inhal prostacyclin oral even brand
remov tyvaso growth lower pt conserv
remov growth expect tyvaso forward year period market
share estim remain pah patient treat per year versu
grow previous
year price histori
biotech compani focus
develop commerci
innov product address unmet
medic need patient chronic
life-threaten condit
analyst certif import disclosur see disclosur
slow loss remodulin tyvaso flolan
dynam model losses/year
adcirca patent loss complet
orenitram hit sale
ralinepag sale
trade compress multipl peer group
believ street underappreci strength
busi model strong experienc
manag team newli launch product pipelin
help bridg patent cliff get back growth
bullish
quarterli sale updat orenitram remodulin
tyvaso effect competitor uptravi gener remoun approv
expect approv competit updat actelion
own uptravi uptak
label updat freedom-ev dinutuximab/
phase readout tyvaso ild copd orenitram
updat best-in-class ip receptor agonist ralinepag
remodulin pump return remodulin growth
orenitram reach sale
success addit indic treprostinil organ
transplant busi and/or oncolog mid-term two three
orenitram sale ramp slows/flatten orenitram
remodulin tyvaso gener loss greater anticip
loss orenitram ip prior patent expir beyond
arriv pt util composit valuat methodolog biotechnolog compani base forward price-to-earnings multipl
net present valu non-gaap estim earn peer index nbi index expect earn compound-annual-growth-rate
next three five year line base case ascrib price-to-earnings multipl
peer group averag due risk uthr loss exclus three lead product remodulin adcirca
 tyvaso discount rate wacc reflect increas risk product sale
downsid risk faster eros remodulin tyvaso adcirca sale expect gener entrant prior
time-frame heighten competit orenitram achiev blockbust statu greater sale next decad
valuat cagrcommentstot revenu oper profit net profit/loss trough year sales/earningsadj reduct share outstand assum us adj ep compound-annual-growth-rate group index nbi indexp group adj ep compound-annual-growth-rate adj ep compound-annual-growth-rate nbi indexp group termin price-to-earnings multipl average median peer-group price-to-earnings due loe risk strong margin ep growth us termin price-to-earnings multipl median price-to-earnings multipl mid-cap peer group opco estimatestermin valu us wacc larg cap biotech averag us discount rate rate per bloomberg due ad risk loe adj ep excl cash price-to-earnings valuat excl cash non-gaap ep growth rate unit
unit statement million product total product adj research adj sell gener licens fees- estim loss contingency- adj total oper oper interest expense- interest income- total expens incom report incom continu adj effect incom tax report incom continu incom discontinu operations- adj net dilut dilut share comp sale outperform
